ECSP078066A - Composiciones y metodos para el tratamiento de síntomas relacionados al ciclo - Google Patents

Composiciones y metodos para el tratamiento de síntomas relacionados al ciclo

Info

Publication number
ECSP078066A
ECSP078066A EC2007008066A ECSP078066A ECSP078066A EC SP078066 A ECSP078066 A EC SP078066A EC 2007008066 A EC2007008066 A EC 2007008066A EC SP078066 A ECSP078066 A EC SP078066A EC SP078066 A ECSP078066 A EC SP078066A
Authority
EC
Ecuador
Prior art keywords
cycle
methods
compositions
treatment
symptoms related
Prior art date
Application number
EC2007008066A
Other languages
English (en)
Inventor
Gary Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP078066A publication Critical patent/ECSP078066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen métodos para tratar un sujeto femenino con síntomas relacionados con el ciclo, que comprenden la administración de una cantidad efectiva de al menos una progestina y al menos un estrógeno a dicho sujeto femenino, donde tal cantidad efectiva se administra diariamente por al menos 100 días.
EC2007008066A 2005-06-28 2007-12-28 Composiciones y metodos para el tratamiento de síntomas relacionados al ciclo ECSP078066A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69507705P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
ECSP078066A true ECSP078066A (es) 2008-01-23

Family

ID=37440889

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008066A ECSP078066A (es) 2005-06-28 2007-12-28 Composiciones y metodos para el tratamiento de síntomas relacionados al ciclo

Country Status (19)

Country Link
US (1) US20070009594A1 (es)
EP (1) EP1896037A2 (es)
JP (1) JP2008544989A (es)
KR (1) KR20080017061A (es)
CN (1) CN101252937A (es)
AR (1) AR054525A1 (es)
AU (1) AU2006263542A1 (es)
BR (1) BRPI0613021A2 (es)
CA (1) CA2612885A1 (es)
CR (1) CR9601A (es)
EC (1) ECSP078066A (es)
GT (1) GT200600280A (es)
IL (1) IL188237A0 (es)
MX (1) MX2007016364A (es)
NO (1) NO20080024L (es)
PE (1) PE20070327A1 (es)
RU (1) RU2007148080A (es)
TW (1) TW200726473A (es)
WO (1) WO2007002862A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
DE102007011486A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2488159A2 (en) * 2009-10-12 2012-08-22 Lyka Labs Limited Emergency contraceptive
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2012129812A1 (zh) * 2011-03-31 2012-10-04 深圳市康泰尔电子有限公司 电子香烟
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
MXPA06013418A (es) * 2004-05-26 2007-01-23 Wyeth Corp Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.

Also Published As

Publication number Publication date
WO2007002862A3 (en) 2007-02-22
KR20080017061A (ko) 2008-02-25
GT200600280A (es) 2007-02-26
CR9601A (es) 2008-05-05
WO2007002862A2 (en) 2007-01-04
RU2007148080A (ru) 2009-08-10
IL188237A0 (en) 2008-06-05
US20070009594A1 (en) 2007-01-11
TW200726473A (en) 2007-07-16
CN101252937A (zh) 2008-08-27
NO20080024L (no) 2008-03-27
JP2008544989A (ja) 2008-12-11
AU2006263542A1 (en) 2007-01-04
BRPI0613021A2 (pt) 2010-12-14
EP1896037A2 (en) 2008-03-12
MX2007016364A (es) 2008-03-05
PE20070327A1 (es) 2007-05-04
AR054525A1 (es) 2007-06-27
CA2612885A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
ECSP088123A (es) Anticoncepcion oral con trimegestona
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
MX2019012657A (es) Inhibidores de tirosina cinasa de bruton.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
CO6400226A2 (es) Micrólido anti-inflamatorio
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
NI200900073A (es) Compuestos de carbamato para su uso en el tratamiento de la depresión.
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
AR062475A1 (es) Combinaciones farmacologicas para el tratameinto de enfermedades de las vias aereas
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
ECSP13012369A (es) Agentes terapéuticos 976
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
AR068608A1 (es) Neramexano para el tratamiento de nistagmo
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.
WO2009075838A3 (en) Treatment of menorrhagia with aromatase inhibitor
TW200616651A (en) Mussel extract composition with enhanced anti-inflammatory activity